Report #2835177

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 53 yrs
State: FL
Recovered: Unknown
Vaccinated: Nov 11, 2024
Onset: Nov 11, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	24M7E	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 53-year-old female patient who received Herpes zoster (Shingrix) (batch number 24M7E, expiry date 06-APR-2026) for prophylaxis. Previously administered products included Shingrix (patient had First dose on January 3rd 2022 Lot number 9EY93, expiry date April 15th 2023 ). On 11-NOV-2024, the patient received the 2nd dose of Shingrix. On 11-NOV-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 24-MAR-2025 Other HCP reported that a patient got first dose of Shingrix on January 3rd 2022 and a late second dose on November 11th 2024, which led to lengthening of vaccinations schedule. (Drug dose administration interval too long)